Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022;
HFpEF represents a significant unmet need in CV medicine due to
its prevalence, poor prognosis, and the absence of clinically proven
therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous
clinical benefits in cardiorenal outcomes of empagliflozin in adults with
HFpEF, which were consistent with the observations in adults with HFmrEF/
HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR
trials establish empagliflozin’s efficacy in heart failure regardless of
ejection fraction – and if approved, empagliflozin would become the first and
only clinically proven therapy to improve outcomes for the full spectrum of
the disease. Therefore, empagliflozin offers a new hope for people living
with heart failure.
Indications/Uses : Advanced renal cell carcinoma in treatment-naive adults w/ intermediate or poor risk; adults following prior vascular endothelial growth factor-targeted therapy. Monotherapy for hepatocellular carcinoma in adults who have previously been treated w/ sorafenib.
Indications/Uses : Control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, or chronic kidney disease (CKD) not on dialysis w/ serum P ≥1.78 mmol/L.
Indications/Uses : Monotherapy or in combination w/ methotrexate for moderate to severe active RA & active psoriatic arthritis in adult patients who have responded inadequately to or are intolerant to ≥1 disease-modifying anti-rheumatic drugs (DMARDs).
Manage Account
Change Password
Sign Out
